Allergan price target raised to $130 from $110 at Argus Argus increased its price target on Allergan after the company reported stronger than expected results. The firm expects the company's earnings to grow at a double digit percentage level over the next three to five years. It keeps a Buy rating on the stock.
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.